The Politics of Patents and Drugs in Brazil and Mexico: The Industrial Bases of Health Policies

Kenneth C. Shadlen

Intellectual property (IP) policies influence trajectories of industrial development and capacities to address humanitarian concerns. As pillars of national systems of innovation, IP regimes drive technological change through their effect on knowledge-creation and knowledge-diffusion. By affecting access to technologically intensive goods, such as pharmaceuticals, IP regimes influence national public health programs. This article bridges these dimensions. Analysis of the politics of drug patents in Brazil and Mexico shows that how IP affects the industrial sector, particularly the pharmaceutical industry, establishes the political-economic parameters affecting countries’ abilities to use IP to promote public health.

Prior to the 1990s neither Brazil nor Mexico (nor many other developing countries) granted patents on pharmaceuticals. Local firms could produce generic versions of new drugs that typically were patented in the OECD. In the 1990s both countries introduced pharmaceutical patents to comply with new international obligations. The World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the IP provisions of the North American Free Trade Agreement (NAFTA) prohibit countries from declaring pharmaceuticals nonpatentable; and the agreements require countries to provide patent holders with strong rights of exclusion over the knowledge contained in the patent. Providing market exclusivity to owners of drugs can raise prices, place drugs out of consumers’ reach, and strain governments’ health budgets. Not surprisingly, the introduction of drug patents was followed by backlash, and by the late 1990s policymakers in many developing countries faced pressures to modify their new IP systems.

Policy in Brazil and Mexico took different courses in response to this changing scenario. Brazil adjusted the IP system to ameliorate the effects that drug patents can have on prices and access; Mexico introduced few adjustments, and where changes were introduced they tended to reinforce and intensify the effects of drug patents. Variation in IP policy can be considered along three dimensions: what knowledge can be owned as property, the rights of owners versus users of property, and the effective duration of property owners’ rights. In Brazil obtaining private ownership over knowledge in the realm of pharmaceuticals has become more difficult, and the rights of third parties to use knowledge simplified. In Mexico impediments have been raised to third parties’ rights to use knowledge, and the effective length of protection extended.

One seemingly obvious explanation for these differences is that Mexico is in NAFTA, while Brazil has no external obligations beyond its membership in the WTO. Although NAFTA places greater restrictions on IP policy, reliance on NAFTA as an explanatory factor is inadequate. Differences in the two countries’ international legal obligations cannot explain the divergence. If it were the case that the reforms introduced by Brazil would, were they transferred to Mexico, violate NAFTA, then NAFTA could partially account for the divergence; it could tell us that Mexico could not take the same path as Brazil on account of its “WTO-Plus” commitments. But the reforms introduced by Brazil would not violate NAFTA; legally, Mexico could imitate Brazil. Moreover, a strict
emphasis on NAFTA cannot explain why Mexico reformed its IP system by moving in the opposite direction as Brazil. Mexico did not simply fail to emulate Brazil’s IP move from away from “TRIPS-Plus” but rather moved to an extended version of TRIPS-Plus.

Nor can the outcome be explained by focusing on political bias. To be sure, the Brazilian governments in the period under study (Cardoso, 1994–2002; Lula, 2002 to the present) were more left-leaning than their Mexican counterparts (Zedillo, 1994–2000; Fox 2000–2006), which perhaps might lead us to expect Brazil to prioritize health. Yet the major health-oriented reforms occurred under President Cardoso, the more centrist of the two Brazilian presidents. This is the same Cardoso that championed the original TRIPS-Plus patent law in 1996, and the subsequent policy shift is not linked to prior changes in ideological disposition or political bias. In Mexico the right-leaning Fox government introduced progressive reforms to the health system to make access to health care a citizen-based rather than employment-based right.5

A political economy explanation for Brazil and Mexico’s divergent trajectories of patent policy focuses on the actors pushing for reform and patterns of coalitional formation and political mobilization. In both countries, drug patents and high prices yielded initiatives for health-oriented IP reform. What varies is who led these initiatives and the extent to which important actors in local pharmaceutical sectors were available as coalition partners. In Brazil the existence of an economically and politically more autonomous local pharmaceutical sector allowed the Ministry of Health to build a coalition in support of IP reform. In Mexico fundamental transformations of the pharmaceutical sector yielded a different terrain. In fact, the reform project in Mexico became commandeered by IP owners and ultimately had the perverse effect of reinforcing the system that was challenged.

Of course, the transformation of Mexico’s pharmaceutical sector is not unrelated to NAFTA, which introduced substantial tariff reduction and revisions to government procurement practices that previously afforded special treatment to local firms. These broad shifts in policy, including pharmaceutical patent protection, induced changes to Mexico’s industrial sector that would ultimately restrict the realm of feasible policy alternatives. NAFTA is indeed significant, then, but in a broad political economy sense. A lesson of this article for scholars of international and comparative political economy is that we need to reorient our attention from the legal to the political economy aspects of international agreements—that is, not the rules per se but how such agreements unleash economic and social changes that in turn affect policy choices.

This article also presents lessons for analysts relying on models of policy diffusion. Diffusion models depict policymaking as an interdependent and interactive process, in which the likelihood that a given policy will be adopted in one country is a function of its adoption (or nonadoption) in other countries. Some analysts apply this logic to the case of IP and drugs. Nunn et al. suggest that Brazilian officials learned from Thailand’s example of using IP regulations to challenge transnational pharmaceutical firms’ pricing practices.7 Cohen and Lybecker suggest that the Brazilian example of health-oriented IP reform can lead other countries to act similarly, citing Mexico as a country so inspired by Brazil.8 Indeed, learning from members of countries’ “peer groups” is a principal mechanism of diffusion in this literature.

Although the idea of reforming the IP system for public health purposes diffused from Brazil to Mexico, the policy did not. The legislative initiative proposed to modify Mexico’s patent system made explicit reference to the Brazilian experience that was to be replicated. But once the diffused idea placed IP on the political agenda in Mexico, the initiative became commandeered by those who wanted Mexico’s patent rules to be made more useful for patent-holding firms to strengthen their property rights and ward off
competition than for the government to negotiate price reductions. The product of diffusion was not Mexico adopting policies that worked in Brazil, but rather policies that were the mirror image of those in Brazil. The explanation for this difference is in the identity of the actors receiving and attempting to implement the diffused idea of health-oriented IP, and the availability of powerful alliance partners for those actors advocating reform. This article thus provides a caution against overstating the significance of ideas and policy communities, and calls for renewed attention to traditional variables such as interests and resources.

**Patents, Pharmaceuticals, and Health Policy**

Prior to explaining the different policy trajectories experienced by Brazil and Mexico in health-related dimensions of IP, it is important to understand the range of variation. In this section a framework is provided that allows us to conceptualize variation with regard to patents, pharmaceuticals, and health policy.9

Patents confer limited rights of exclusion over inventions that are novel and non-obvious and have industrial utility. Although granting a patent turns knowledge into private property, the rights of owners over their property are limited in that they are not automatic, not absolute, and not permanent. Patents are granted only where applicants demonstrate that their inventions satisfy the criteria of patentability. With application and examination central and prior to the process of establishing ownership, governments can control what knowledge becomes private property within their territory. Because the establishment of ownership follows and depends on the examination of patent applications, governments can control what knowledge becomes private property within their territory. Another limitation is that patent rights include various exceptions to patent holders’ ability to control the use and distribution of their property. Patent regimes include provisions by which third parties can, without requesting permission, use knowledge that is owned by someone else. They also include provisions that allow third parties to receive permission from the state to use other actors’ privately owned knowledge in ways that would otherwise constitute violations of patent holders’ rights. Lastly, patents expire. At some point the private property enters the public domain, where access to and use of the knowledge is unrestricted.

These three limitations map onto lines of political conflict over what can be owned privately, between the rights of owners and users of private property, and over the duration of rights. These lines of conflict, in turn, map roughly onto axes of policy variation10. The rows in Table 1 take us from a limitation to a political conflict and then provide health-related policy examples.

**Table 1 Law, Politics, and Health Policy**

<table>
<thead>
<tr>
<th>Limitations</th>
<th>Political Conflict</th>
<th>Health-Related Policy Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not automatic</td>
<td>What can be owned</td>
<td>Pharmaceutical patents “Pipeline patents”</td>
</tr>
<tr>
<td>Not Absolute</td>
<td>Rights of owners vs. users</td>
<td>Compulsory licenses Parallel imports</td>
</tr>
<tr>
<td>Not Permanent</td>
<td>Duration of rights</td>
<td>Post-patent generic entry (early working provisions, drug registration procedures)</td>
</tr>
</tbody>
</table>
With regard to conflicts over what sort of knowledge can be owned privately, the most important policy issue is whether or not countries grant pharmaceutical patents. As indicated, many developing countries did not do so prior to the 1990s, but TRIPS (and NAFTA) requires that countries grant patents on pharmaceutical products and processes.\textsuperscript{11}

A second policy issue is how to deal with inventions that are not new but that were not patented when they were new because the previous regime did not allow the sort of knowledge to be patented. If a country began granting pharmaceutical patents in 1995, for example, a drug invented in 1990 would not have been eligible for a patent when it was new. The novelty requirement would also make the drug unpatentable in 1995, even with the introduction of pharmaceutical patents, because it was no longer new. Since drugs are patented before marketing authority is secured, the 1990 drug would most likely be undergoing clinical trials in 1995—it would be in the “pipeline.” How do countries introducing pharmaceutical patents treat drugs in the pipeline? On this dimension NAFTA exceeds TRIPS by obligating countries to offer “pipeline patents.”\textsuperscript{12}

Policy areas that correspond to conflicts over the rights of owners versus users concern compulsory licenses (CLs) and parallel imports. CLs allow domestic entities (public or private) to import, produce, and distribute patented goods without the patent holders’ consent. TRIPS and NAFTA allow countries to determine the grounds on which they grant CLs, provided that a set of procedural conditions (such as prior negotiations with the patent holder and payment of royalties).\textsuperscript{13} In the case of CLs granted during times of national emergency or for government use, countries are released from the obligation of prior negotiations.\textsuperscript{14} Because potential delays introduced by negotiations are removed with this latter type of CL, these CLs are easier and quicker to grant and, arguably, most relevant for discussions of health.

Parallel importation consists of allowing patented goods to enter the market once patent holders have placed the goods on the market elsewhere. Parallel imports can help ensure affordability of patented products by facilitating arbitrage and thus constraining patent holders’ ability to set monopoly prices. TRIPS allows countries to engage in parallel importation by adopting international doctrines of patent exhaustion; that is, once products are placed on the international market, patent holders’ exclusive rights are exhausted. NAFTA prohibits parallel importation by requiring national doctrines of patent exhaustion.

Health-related policy areas corresponding to conflicts over the length of rights regard post-patent generic entry. When patents expire and knowledge enters the public domain, new actors gain rights to participate in markets that were reserved for patent holders. How quickly new actors enter markets and the subsequent competitive effects are felt in terms of reduced prices depends on a number of important policies, particularly early working provisions and procedures for registering generic drugs. Early working provisions allow firms to use patented knowledge and produce generic versions of patented drugs to obtain marketing approval once patents expire.\textsuperscript{15} Without such provisions firms might be infringing patents by producing generic versions prior to the patents’ expiration. Yet if firms must wait until patents expire to produce generic versions and apply to health authorities for authorization, patent terms are effectively extended by the amount of time it takes to complete these not-insignificant steps. Early working provisions, then, by allowing generic firms to use patented knowledge to prepare for market entry, can expedite competition at the point that patents expire. TRIPS and NAFTA both permit early working provisions.\textsuperscript{16}

Some pharmaceutical firms opt to launch generic versions prior to the end of patent terms, believing that their follow-on products do not infringe existing patents or that the patents in question are invalid. Since marketing drugs depends on authorization from health authorities, the subsequent question is whether and how the activities of IP and
health officials are coordinated. Neither TRIPS nor NAFTA addresses this. More recently, the United States has pushed strongly for a form of coordination known as “linkage,” whereby health authorities consult with IP authorities and deny registration to drugs when patents are in force. While this form of coordination seems unproblematic on the face of it (if the drug is patented, then the sale of generic versions would be illegal), many developing countries resist pressures to proceed in this direction, arguing that linkage inappropriately transfers the burden of defending patents from the private rights-holder to the public. In any case, this form of linkage, though included in more recent regional and bilateral trade agreements (RBTAs) negotiated with the United States, is not in NAFTA.

Table 2 contrasts the WTO and NAFTA with regard to the health-policy dimensions of the two agreements’ IP provisions. While it is clear that there are differences, such as pipeline patents and parallel imports, the similarities are certainly greater.

### Table 2 IP and Health Policy: WTO vs. NAFTA

<table>
<thead>
<tr>
<th>Policy Issue</th>
<th>WTO (TRIPS)</th>
<th>NAFTA (Chapter 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical patents</td>
<td>Required (product and process)</td>
<td>–</td>
</tr>
<tr>
<td>Pipeline patents</td>
<td>Not required</td>
<td>Required</td>
</tr>
<tr>
<td>Compulsory licenses</td>
<td>Permitted; ample discretion</td>
<td>–</td>
</tr>
<tr>
<td>Parallel imports</td>
<td>Permitted</td>
<td>Not permitted</td>
</tr>
<tr>
<td>Early working provisions</td>
<td>Permitted</td>
<td>–</td>
</tr>
<tr>
<td>Drug registration procedures</td>
<td>Not addressed</td>
<td>–</td>
</tr>
</tbody>
</table>

Note: – indicates that NAFTA and TRIPS are identical

The WTO’s and NAFTA’s provisions indicate the parameters of what countries can and cannot do, but not what they actually do. Table 3 presents the main characteristics of the Brazilian and Mexican patent regimes implemented in the 1990s. Both countries greatly exceeded their new obligations, making ownership easy to obtain over a wide variety of pharmaceutical and pharmaconal products and processes, and giving owners strong and effectively long rights of exclusion. From a public health perspective, both countries’ patent regimes were worrisome. For example, both countries offered pipeline patents, neither allowed parallel imports, both had only rudimentary mechanisms for compulsory licenses to deal with health concerns, and neither had early working provisions. As a result of these “TRIPS Plus” patent regimes, more drugs would become patented in both countries and it would be difficult to rely on generic competition to reduce prices. Beginning in the late 1990s, however, the two countries diverge in dramatic fashion. The subsequent sections explain this divergence, drawing our attention to the important role of local pharmaceutical industries in coalitions for health-oriented patent reform.

### Table 3 Health-Related IP Policy: Common Origins

<table>
<thead>
<tr>
<th>Policy</th>
<th>Brazil</th>
<th>Mexico</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compulsory licenses</td>
<td>Yes (basic, Art. 77)</td>
<td>Yes (basic, Art. 71)</td>
</tr>
<tr>
<td>Parallel imports</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Early working provisions</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Linkage</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Note: The shaded text indicates important differences.
Brazil: From TRIPS Plus to “TRIPS Just”

In the late 1990s and early 2000s, health-related aspects of Brazil’s patent regime underwent substantial modifications. Obtaining pharmaceutical patents was made more difficult, the patent law was modified to facilitate government efforts to lower prices through compulsory licensing, and the government enacted measures to encourage competition with generics. The nature of the Brazilian government’s demand for patented and expensive drugs made health-oriented IP reform a high priority, and the political organization and structure of the Brazilian pharmaceutical industry made reform politically feasible.

The Brazilian government’s demand for drugs was strong and relatively inelastic to price on account of the Ministry of Health’s (MH) extensive obligations to provide free medicines. These obligations are rooted in the 1988 Constitution, which establishes the right to health, including access to essential medicines through the new national health care system (SUS) as a universal right. Government demand was particularly shaped by the HIV/AIDS epidemic. Although Brazil’s adult prevalence rate of 0.6 percent is not particularly high by international standards, the country stands out for its early (since the late 1980s) and comprehensive approach toward prevention and treatment. Importantly, a 1996 Law guaranteed free antiretroviral (ARV) treatment through the MH’s National HIV/AIDS Program, and intense social mobilization further reinforced the government’s obligations.17

Brazil’s approach to HIV/AIDS treatment affected the government’s demand in such a way as to make IP reform an imperative. Because ARVs treat but do not cure HIV/AIDS, they need to be taken indefinitely; and patients need to change treatment regimens as immunities develop. By the late 1990s the annual per patient cost of treatment in Brazil was nearly US$5,000 and ARVs already consumed one-third of the MH’s drug budget, and this was at a time when treatment featured almost exclusively unpatented drugs. As more people began treatment and as patients migrated to expensive second-line regimens based on drugs that were patented under Brazil’s new IP law, the program would be unsustainable.18

Since 1999, then, the government took a range of measures to improve the capacity of the National HIV/AIDS Program (and the SUS more generally) to acquire less expensive, generic versions of newer drugs from both foreign and local suppliers. The MH’s initiative to lower costs via promotion of generics led to three important modifications of Brazil’s new IP system: health authorities gained prominence in reviewing patent applications, compulsory licensing provisions were made more flexible and easier to use, and regulatory reforms were introduced to expedite post-patent generic entry.

Any pharmaceutical patent application that is approved by the National Institute for Industrial Property (INPI) is sent to the MH for review. The patent is issued only after IP officials in the Ministry’s health surveillance agency (ANVISA) issue “prior consent.”19 This reform, introduced by decree by President Cardoso in 1999 and converted into law in 2001, aimed to provide the MH with an instrument to influence the patent examination process, influence that it would otherwise lack on account of INPI being situated within a different ministry.

The prior consent requirement makes it more difficult to obtain private rights of exclusion over knowledge for pharmaceuticals. Many patent applications are not for new molecular entities (NMEs) but rather revised versions of NMEs that are already patented, raising the question of how patent examiners define “novelty.” ANVISA’s health-focused examination is significantly stricter than INPI’s. Whereas INPI is criticized by health activists and lawyers for adopting an overly broad definition of novelty, ANVISA denies patents to drugs that lack “genuine” novelty and where it appears that the invention is nothing more than a mathematical combination of structures already known.
adjudges that providing exclusive rights would be harmful to public health. Typically ANVISA uses its authority to prevent patents that, by its judgment, would extend the terms of existing patents. As Table 4 indicates, 53 applications approved by INPI have been rejected by ANVISA since the prior consent process was initiated in 2001. Perhaps more critically, of the 68.9 percent of the applications that ANVISA has approved, in 42 percent of these cases the applicant first had to reduce the breadth of the patent’s claims.

Table 4  ANVISA’s Prior Consent (through July 2008)

<table>
<thead>
<tr>
<th>Decision</th>
<th>Number of Cases</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approvals</td>
<td>752</td>
<td>68.9</td>
</tr>
<tr>
<td>Denials</td>
<td>53</td>
<td>4.9</td>
</tr>
<tr>
<td>Pending (as of July 2008)</td>
<td>122</td>
<td>11.2</td>
</tr>
<tr>
<td>Other*</td>
<td>165</td>
<td>15.1</td>
</tr>
<tr>
<td>Total</td>
<td>1092</td>
<td>100.0</td>
</tr>
</tbody>
</table>

*Includes applications returned to INPI for further documentation and because determined not to be pharmaceutical patent applications

Source: ANVISA

No aspect of the global politics of IP has received so much attention as compulsory licenses, and Brazil has been at the forefront of these debates. The 1996 LPI includes multiple articles that address CLs, the most significant for our purposes being Article 71 covering national emergencies and situations of “public interest.” Presidential directives in 1999 and 2003 reformed Article 71 to make it more useful and thus increase the MH’s capacity to leverage price reductions from patent-holding pharmaceutical firms. These revisions gave clearer definitions of national emergency and public interest and simplified the mechanism for issuing CLs by giving the MH greater authority to act. Importantly, the 2003 directive stipulates that private firms supplying the government constitutes “public use” and is thus acceptable under Article 71, and also requires patent owners to transfer technological knowledge in the case of CLs.

The threat of a CL is a bargaining tool used to entice patent holders to make their products available at lower prices. The effectiveness of the bargaining tool, however, depends on the credibility of the threat. The reforms to Article 71 make the Brazilian government’s threats more credible by making CLs easier to issue and less vulnerable to appeal, and by increasing the government’s ability to secure the relevant drugs from alternative suppliers.

Since 2001 the MH has repeatedly used the CL instruments to obtain price reductions on second-line ARVs that consume a disproportionate share of the MH’s drug budget. The key ARVs (patent holders) are efavirenz (Merck), lopinavir/ritonavir (Abbott), and Nelfinavir (Roche), which account for roughly 60 percent of the government’s ARV expenditures. In August 2001, for example, the MH announced it would issue a compulsory license on nelfinavir, and Roche responded by reducing the price. Similar episodes occurred with Roche and Abbott, with Merck in 2003, and then again with Abbott in 2005. In 2007, following protracted negotiations with Merck, Brazil issued a CL on efavirenz. Note that these drugs are patented in Brazil because of the inclusion of pipeline patents in the 1996 LPI. Thus, to an important extent, the reforms to, and exercise of, the CL provisions can be understood as efforts to ameliorate the effects of the TRIPS Plus LPI.

Negotiations have not always been entirely successful. The 2005 agreement with Abbott left the price of lopinavir/ritonavir well above Abbott’s most discounted international price, for
example, and the MH is widely criticized for not issuing more CLs.\textsuperscript{26} Yet the MH’s strategy, its shortcomings notwithstanding, has resulted in significant cost savings, even as patented second-line treatments play increasingly greater roles in the national treatment program.\textsuperscript{27} In fact, while the affordability of second-line ARVs provided the main impetus for IP reform, the modifications have yielded lower drug prices across the board.\textsuperscript{28}

The Brazilian strategy to introduce generic competition also included amending the 1996 LPI to introduce an early working provision, which allows generic firms to prepare for market entry at the moment of patent expiration.\textsuperscript{29} Importantly, Brazilian authorities refuse to adjust terms for patents granted under the pipeline mechanism. That is, if a patent had a priority date from its application in the United States of January 31, 1987, for example, and was granted in Brazil under the pipeline mechanism in 1999, the patent would be due to expire in both the United States and Brazil on the same day, January 30, 2007. And even if the United States were to extend the expiry date by two years, until January 2009, it would still expire in 2007 in Brazil. The transnational sector pushes strongly for adjusting patent terms in this way and regularly demands this in court, but doing so is not the norm in Brazil.\textsuperscript{30} The bias against adjustments of patent terms provides generic producers with incentives to utilize the early working provision. The effectiveness of the system is further enhanced by ANVISA’s policy of granting rapid approval of products that satisfy health criteria, leaving questions of potential patent infringement to be contested in courts.

While the nature of demand has driven the Brazilian government to introduce these health-oriented IP reforms, the support of the Brazilian pharmaceutical sector makes doing so feasible. The reforms, not surprisingly, have drawn strong criticism from the transnational pharmaceutical sector from both its representatives in Brazil (INTERFARMA) and the United States (PhRMA). Actors that once heaped praise on Brazil for its “modern” 1996 LPI now complain of piracy and theft.\textsuperscript{31} But these attacks do not isolate the government, which can rest on the support of a coalition of actors representing the national pharmochemical (ABIFINA) and pharmaceutical (ALANAC, ALFOB, and ProGenéricos) producers. These organizations—some of which unsuccessfully resisted the 1996 LPI—act as a bulwark against INTERFARMA, consistently presenting positions contrary to those of the transnational sector. When INTERFARMA assailed the reforms introduced in 1999 and 2000 or the 2007 CL, for example, ABIFINA quickly came to the MH’s defense.\textsuperscript{32}

The existence of a coalition supportive of health-oriented IP reforms is partially a function of state policy. After all, the local pharmaceutical sector benefited from significant government investment in research and production, much of it through the MH itself.\textsuperscript{33} The Ministry, acting as “health entrepreneur,” does not just purchase drugs but also takes an active role in their production.\textsuperscript{34} Public sector labs are important suppliers to the government, and, earlier in the production chain, the state works with private firms to help them develop synthesis technologies, produce necessary intermediates, and acquire capacities for reverse-engineering active principal ingredients (APIs).

Economic and technological collaboration between the public and private sectors created conditions for a political alliance and hospitable ground for the government’s health-oriented IP reforms. The transnational sector opposed the government at nearly every step, but INTERFARMA does not monopolize the sector politically. The existence of a national pharmaceutical sector with interests distinct from the transnationals and with productive capacity retained from an earlier period of industrialization presented the MH with friendly and cooperative interlocutors. Indeed, the 2003 presidential directive on CLs was drafted by a lawyer who works as an advisor
to ABIFINA.\textsuperscript{35} It is essential to emphasize that the virtuous circle, whereby the government invests in industry and industry supports the government’s IP reforms, is possible because of the condition of the local pharmaceutical sector. Even with the introduction of pharmaceutical patents and in the context of trade liberalization and an overvalued currency, Brazilian firms retained market share in the 1990s. By the time health-related IP reforms became politically salient, local firms still accounted for roughly one-quarter of sales and dominated the nascent generics market, and pharmochemical firms retained twice the market share of Chinese and Indian combined imports.\textsuperscript{36} A critical point here is the remaining capacity to produce final drugs and APIs, which is a legacy of the import-substituting period, particularly the push for backward integration of the pharmaceutical sector in the 1980s.\textsuperscript{37} Furthermore, the “late” introduction of pharmaceutical patents in 1997 meant that the potential denationalizing effects had not yet materialized.\textsuperscript{38} Because Brazilian firms were still capable of benefiting from the government’s strategy, they were available alliance partners.

Mexico: From TRIPS Plus to NAFTA Plus

Policy in Mexico followed a fundamentally different trajectory. Whereas Brazil implemented reforms to ameliorate the effects of patents on drug prices, Mexico’s policies reinforce these effects. Changes to Mexico’s patent law make use more difficult and complicate the process by which CLs can be issued, and modest steps to encourage post-patent generic competition were introduced in a self-undermining fashion. The explanation for this different path is rooted in the Mexican government’s less comprehensive response to the HIV/AIDS epidemic, which made IP reforms less compelling, and in the transformations of the pharmaceutical sector, which not only made coalition-building for health-oriented IP reform less feasible but facilitated a countermobilization on the part of patent owners.

Although the affordability of medicines became a prominent issue in Mexico in the late 1990s, as prices increased significantly above the rate of inflation in the years following the 1994 devaluation of the peso, the nature of government demand reduced the sensitivity to such changes. State provision of discounted and free medicines was far from universal, extending only to workers in the formal sector (IMSS) and government employees (ISSSTE). Nor did Mexico’s Secretariat of Health (SH) face Brazilian-like obligations with regard to ARVs. Most HIV/AIDS treatment was provided outside of the state system and the uninsured generally lacked access.\textsuperscript{39} Thus, the SH had less cause for alarm in the face of higher prices and less motive to reform the patent system.

Rather than coming from within government, the initiative for health-oriented patent reform came from a segment of the local pharmaceutical sector that emerged in the 1990s in response to economic crisis and the limited coverage of IMSS/ISSSTE. In the late 1990s and early 2000s a chain of pharmacies selling nonbioequivalent generics under the mark Similares (Similars) expanded in low-income areas throughout the country.\textsuperscript{40} The emergence of Farmacias Similares gave local firms that had traditionally supplied the state sector opportunities to sell to private pharmacies. The actors in the chain were closely related, in fact, with the leading producer of nonbioequivalent generics (Laboratorios Best) owned by the same person who owned the Farmacias Similares chain, a physician-pharmacist-industrialist named Victor González Torres, also known as “Dr. Simi.”\textsuperscript{41}
The Similares sector and its allies in Congress spearheaded the initiative to reform the patent system. In December 2002 Dr. Simi’s nephew, a Green Party (PVEM) member of the Chamber of Deputies, presented an initiative that would reform the 1991 LPI by reducing patent terms to ten years in the case of serious health situations. The PVEM initiative would have violated Mexico’s TRIPS and NAFTA requirements for twenty-year patent terms, but instead of rejecting the proposal out of hand, the Science and Technology Commission (CCyT) modified it. For all the proposal’s faults, its motivations and context were not to be ignored. Escalating drug prices were making access to medicines a growing problem, and as the initiative’s authors emphasized, other developing countries (such as Brazil) were demonstrating the feasibility of health-oriented patent reforms. Thus, the president of the CCyT acknowledged the concerns expressed by the bill’s sponsors and decided to rewrite the proposal with proper legal assistance.42

While the original proposal addressed patent terms (Article 23), the revised bill addressed CLs (Article 77), an area where Mexico had discretion under TRIPS and NAFTA. In March 2003 the CCyT approved a modest reform that would increase the capacity of the SH to issue CLs in the case of health emergencies. The key elements were to make a state of “serious illness” declared by the SH a ground for CLs, to simplify the process by which serious illness is declared, and to assure rapid issue of CLs at low royalties.

The March 2003 bill, similar in many ways to Brazil’s 1999 CL reform, drew a sharp reaction from the transnational pharmaceutical industry and its local representatives. Government officials and legislators found themselves besieged by letters, faxes, e-mails, phone calls, and personal visits from the transnational sector’s trade association (AMIIF), Mexico’s leading law firms, the USTR, and foreign embassies (for example, of the United States and Switzerland).

The transnational sector did not just react defensively but went on the offensive, converting the threat into an opportunity. AMIIF had attempted to terminate the patent reform project, though once it was kept alive by the CCyT, AMIIF and its allies mobilized to secure a reform that would make the granting of CLs less likely than under the 1991 law.43 The campaign was successful, as the transnational sector essentially commandeered the initiative. The Fox government, never compelled by IP reform in the first place, joined the counteroffensive. The Secretary of Government’s legislative liaison insisted that the March 2003 version could not proceed and provided the CCyT with a revised text.44 This new version, which was passed by the full Chamber of Deputies and Senate and then signed into law by President Fox in 2004, increases the obstacles to issuing compulsory licenses by making the process by which serious illness declared more complicated, removing serious illness as a ground for a CL, and requiring high minimum royalty rates.45

The transnational sector also secured favorable changes with regard to post-patent generic entry. In September 2003, at the same time as the reform to the patent law was in the Senate, the Fox government announced a new linkage system that requires health authorities to consult with the IP office and deny marketing authority to drugs where patents remain in effect. Thus, while Brazil’s prior consent measure integrates health criteria into patent policy, Mexico’s linkage system subordinates health policy to patent criteria.

Mexico also introduced an early working provision at this time, but this is largely undermined by the transnational sector’s ability to secure routine adjustment of the expiration dates on pipeline patents.46 The Mexican IP law stipulates that pipeline patents expire in Mexico on the same date as they expire in the first country where the
patent was filed. These clauses, though contested in courts, essentially commit Mexico to adjust expiry dates. Because patent terms are adjusted in Mexico when they are adjusted in the original country, industry actors cannot know when a drug’s patent will expire, which makes it difficult to take advantage of any opportunities created by the early working provision.

The changes introduced to Mexico’s IP system (and health regulatory structure more generally) mean that the prices of patented drugs remain higher in Mexico. Patent-holding pharmaceutical firms do not fear CLs, and thus feel little compulsion to reduce prices. Abbott, for example, prices its patented version of lopinavir/ritonavir at more than five times the Brazilian price, but the Mexican government lacks the instruments to negotiate price reductions. More accurately, such instruments, as they previously existed, were dulled by the reforms of 2003–04.

To make sense of the perverse experience of IP reform in Mexico, where an initiative to enhance the rights of knowledge-users ended up yielding a set of changes that strengthen the rights of knowledge-owners, it helps to consider the changing political economy of the pharmaceutical sector. In contrast to Brazil, where INTERFARMA’s positions are regularly countered by rival actors, in Mexico AMIIF dominates the sector economically and politically. Of course, individual Mexican firms would benefit from Brazilian-style patent reforms, as originally approved by the CCyT, yet outside of Farmacias Similares (and its subsidiary firms and suppliers) not even the local pharmaceutical sector provided support for the favorable version of the CCyT’s initiative or opposed the revised and unfavorable version. Nor did they much contest the linkage system.

The early and, with the inclusion of pipeline patents, retroactive introduction of pharmaceutical patents transformed Mexico’s pharmaceutical sector. Through the mid–1980s the national pharmaceutical sector thrived on reverse-engineering unpatented drugs.47 By the late 1990s, however, trade liberalization had undermined the pharmochemical sector and patent protection transformed the industrial structure. The decline of local firms in Mexico was much more accentuated than in Brazil. Mexican firms account for less than 15 percent of sales. In fact, nearly two-thirds of Mexico’s pharmochemical firms disappeared from 1987 to 1998 as the sector became subject to import competition and patent protection.48

The transformation in industrial structure is reflected in the realm of politics. Whereas AMIIF and the principal association representing local firms (CANIFARMA) were arch-enemies during the IP debates of the 1980s and early 1990s, by the early 2000s they were speaking with one voice. Indeed, the organizations were formally fused, with the president of CANIFARMA an invited member of AMIIF’s board and the CANIFARMA’s two-year presidency alternating between Mexican and foreign firms. Nor does Mexico have an equivalent to Brazil’s ABIFINA. Instead, the pharmochemical sector’s representative body consists of a small unit within a broader multisectoral industrial chamber of manufacturing industries (CANACINTRA), which itself experienced dramatic decay in this period.49 In short, Mexico’s pharmaceutical and pharmochemical producers could not articulate positions independent from the transnational sector’s because the local sector was neither economically nor politically independent.

A potential source of support for the CCyT’s initiative was from the segment of industry that focuses on bioequivalent generics, represented by the National Pharmaceutical Association (ANAFAM). Yet this organization found itself in stark decline in the late 1990s and early 2000s, with a shrinking membership. In fact, ANAFAM did not represent a national pharmaceutical sector either, for this segment
was undergoing trans-nationalization of its own, with international generic firms purchasing long-established Mexican firms.\textsuperscript{50} ANAFAM’s strategizing in response to the CCyT initiative reflects this politically precarious position. ANAFAM advised CANIFARMA that, despite the likelihood that members of the two organizations would benefit from the proposed reform, they should lay low and refrain from showing support to avoid the appearance of conflicts of interest.\textsuperscript{51} Fighting on two fronts—against AMIIF and Similares—and politically unstable on account of its own transnationalization, the bioequivalent generics sector was in no position to lend its support to the CL initiative, nor to oppose the revised pro-AMIIF version.

CANIFARMA and ANAFAM’s economic and political weakness meant that AMIIF came to dictate the positions of the pharmaceutical industry on matters of policy. The lone alternative voice came from the Similares sector—purveyors of nonbioequivalent medicines (which most countries, including Mexico, are eliminating from the market) and closely tied to the fringe PVEM. AMIIF, thus, was able to do better than prevent Mexico’s patent law from being reformed—a la Brazil—to simplify CLs. The transnational sector engineered reforms to Article 77 and the health regulatory system that strengthen the rights of knowledge-owners.

**Conclusion**

In this article a framework is introduced for comparing countries’ patent systems, and Brazil and Mexico’s distinct trajectories of patent policy since the late 1990s are explained. On each of three dimensions—what knowledge can be owned as property, the rights of owners versus users of property, and the effective duration of property owners’ rights—the Brazilian tendency has been to increase the capacities of knowledge-users while the Mexican tendency has been to reinforce the rights of knowledge-owners.\textsuperscript{52}

This article brings politics to bear on a topic that has been dominated by analyses of laws and formal international agreements. Comparing Brazil and Mexico, for example, focusing on external legal obligations calls attention to NAFTA, which includes IP provisions that differ from TRIPS (Table 2). Yet this is an insufficient explanation. As of the late 1990s the health dimensions of the two countries’ patent systems were similar, and the subsequent divergence did not conform to unique obligations that Mexico had under NAFTA.\textsuperscript{53} All the reforms implemented in Brazil would be acceptable under NAFTA too.

The divergence is attributable to distinct interests and alliances over IP policy. In Brazil the nature of government demand for patented and expensive drugs made health-oriented IP reform a high priority, and the political and economic characteristics of the pharmaceutical sector facilitated the creation of a coalition for IP reform. In Mexico, however, a less comprehensive response to the HIV/AIDS epidemic made IP reforms less compelling, and a transformed pharmaceutical sector not only prevented coalition-building for health-oriented IP reform but facilitated a countermobilization that strengthened the rights of patent owners. The argument is not that local pharmaceutical sectors drove policy change, but that their economic and political characteristics affected the receptiveness to such policy initiatives. The Brazilian reforms were state-led, but they were feasible because the government could elicit the support of local actors that had retained valuable economic and political assets. Different legacies of industrialization combined with Brazil’s comparatively later retiring of industrial policies and introduction of
pharmaceutical patents meant that Brazil was less advanced along the pharmaceutical-denationalization curve than Mexico.

To the extent that the argument rests on the actions of Brazilian and Mexican health officials, it is not a matter of institutional structure but power vis-à-vis society. Brazil’s IP reforms were spearheaded by Health Minister José Serra, a close ally of the President who would run for the presidency in 2002, and Brazil’s health activism certainly needs to be understood in this larger political-electoral context. Yet Mexico’s Health Secretary Julio Frenk was a prominent figure within President Fox’s cabinet as well. Mexico moved toward universalizing health coverage under Frenk’s tutelage, a measure that reflects the Secretary’s authority. Yet state power is situational and relational, depending on what societal allies are available and against what opponents. The nature of Mexico’s transnationalized pharmaceutical sector meant that Frenk could not, and therefore would not, attempt to go down the Brazilian path.

To understand the importance of industrial structure, consider a counterfactual—the Mexican government was not motivated to pursue health-oriented IP reform, but suppose that it were so inclined. It is difficult to imagine how the SH could have created the sort of pro-reform coalition as Brazil’s MH did, because the early introduction of pharmaceutical patents and the subsequent transformation of the sector deprived it of potential allies. Indeed, on a number of issues related to health provision, Mexico’s SH sought the collaboration of local producers only to be stymied by AMIIF’s dominance of the sector and the absence of local interlocutors. Industrial transformation and denationalization have political as well as policy consequences.

Emphasizing industrial structure aims to supplement (not substitute) prevailing emphases on Brazilian civil society’s role in pushing government to make AIDS treatment a high priority and introduce health-oriented IP reforms. Whatever inspired the Brazilian government to act, local industry was crucial in not blocking, and indeed eventually supporting, the reforms. The difference with Mexico, where domestic industry ended up actively opposing health-oriented IP reforms and effectively supporting a strengthening of patent holders’ rights hand-in-hand with the transnational sector, is stark.

To conclude, it is worth returning to the two areas where IP matters: technology and industrialization, and health and humanitarianism. The analysis bridges these two realms, for the key variable explaining differences between Brazil and Mexico has been the existence of indigenous pharmaceutical and pharmochemical capacities. An earlier generation of scholarship argued that promotion of local pharmaceutical sectors may be important for industrial development, but that because promotional measures may also raise the final prices of medicines, such strategies were less beneficial on the humanitarian axis of development. The argument and findings in this article invert this line of reasoning: to use IP to achieve humanitarian goals, countries also need to use IP to achieve industrial goals. They need local pharmaceutical industries that can act as a countervailing political force to the transnational sector. Indeed, whereas previous scholarship has depicted pharmaceutical development as good for industrialization but not for humanitarianism, this article shows how pharmaceutical development may be good for both, because it makes humanitarianism politically feasible in the world of strong IP. The key to reforming patent systems to increase access to drugs is the presence of economically and politically autonomous, national pharmaceutical industries as coalition partners for those advocating such reforms.
NOTES

The British Academy and Nuffield Foundation financed the research for this article. Rodrigo Martínez assisted in Mexico; Eduardo Fernández provided invaluable support in Brazil. I thank Sarah Brooks, Matthew Flynn, Kevin Gallagher, Cori Hayden, Lawrence King, Ariane McCabe, Tim Power, Diego Sánchez-Ancochea, Andrew Schrank, and Pamela Starr for suggestions, and the journal’s referees for their constructive reviews.

1. Until the 1970s many developed countries (for example, Italy and Japan) did not issue pharmaceutical patents either.

2. The term “generic” is used to refer to drugs unprotected by patents. Some definitions also stipulate that the drug be unprotected by trademark. Although generic does not mean the same thing everywhere, Brazilian and Mexican regulations share a common definition. Núria Homedes and Antonio Ugalde, “Multi-source Drug Policies in Latin America: Survey of 10 Countries,” Bulletin of the World Health Organization, 83 (January 2005): 64–70.


5. In fact, Fox’s appointment as Health Secretary was well known for his long-standing call for universal health coverage.


9. For detailed discussion, see Carlos Correa, Integrating Public Health Concerns into Patent Legislation in the Developing Countries (Geneva: South Centre, 2000); CIPR, chap. 2.

10. In fact, some policy areas are relevant to multiple lines of conflict.

11. Countries that did not grant pharmaceutical patents prior to 1995 had until 2005 to begin doing so.

12. In addition to stretching the definition of “novelty,” the problem with pipeline patents is that they are not examined but rather revalidated.

13. Compare the nearly identical CL provisions of TRIPS Article 31 (http://www.wto.org/english/tratop_e/trips_e/t_agm3c_e.htm#5) and NAFTA Article 1709.10 (http://www.sice.oas.org/Trade/nafta/chap-171.asp).

14. This provision, that when CLs are issued on grounds of national emergency countries are released from procedural obligations, is often misrepresented to suggest that countries can only issue CLs in national emergencies. To repeat, countries can issue CLs on whatever grounds they establish in national legislation, but in times of national emergency (and government use) they can bypass negotiations.

15. Formally, early working (also called “Bolar”) provisions are examples of limiting owners’ rights of exclusion, but where they most matter regards the effective duration of owners’ rights.

16. Such provisions do not shorten patent terms but rather eliminate the effective extension of terms that is yielded by leaving a single firm with market exclusivity despite the patents’ expiration. I am not addressing data exclusivity.

Without Equity: Failures of Reform in Brazil [Pittsburgh: University of Pittsburgh Press, 1996], chap. 7), the National HIV/AIDS Program offers an exception.


19. ANVISA’s IP division, established in 2001, was housed in INPI’s Rio office building.

20. Does showing a “second use” for an existing drug constitute “novelty” and warrant a patent?


22. This policy corresponds to two types of conflicts, what knowledge can be owned and also the duration of private rights.


24. Although presidential directives are meant to establish implementation guidelines and not formally reform laws, they are often substantive, as in this case.

25. A different article (Art. 68, which authorizes CLs where a patented good is not manufactured locally) was the subject of a WTO case that the United States filed and later withdrew.


29. Introduced by presidential decree, then converted into law in 2001.


31. These complaints and accusations were repeated in multiple interviews with representatives from INTERFARMA, patent lawyers in Brazil, and USTR officials. See, as examples, Frederico Vasconcelos, “Mudanças na lei desagrada múltis,” Folha de São Paulo, 21 February 2000; Lawrence A. Kogan, “Brazil’s IP Opportunism Threatens U.S. Private Property Rights,” Inter-American Law Review, 38 (Fall 2006): 1–139; and Igor Leonardo Guimarães Simões, “A Guerra das patentes farmacêuticas,” Jus Navigandi, 9 (28 May 2005). See also the USTR’s annual “Special 301” reports on IP, and PHARMA’s submissions to these reports.

32. See, for example, Vasconcelos, “Mudanças na lei desagrada múltis”; Marcos Oliveira, “A falácia da quebra de patente,” Jornal do Commercio, 10 April 2006 (column by ABIFINA’s vice-president published in newspapers throughout Brazil); and Eduardo Costa and Nelson Brasil, “A Emancipação do Programa anti-Aids,” Jornal de Brasilia, 15 November 2007. Brazilian industry’s position is not uniform, of course, nor its support rock-solid. On some issues, particularly those affecting patenting of incremental innovations, local firms are ambivalent and divided. Shadlen, “Political Contradictions of Incremental Innovation.”

33. Of Brazil’s eighteen government-linked pharmaceutical producers, the most important is part of the MH: Farmanguinhos, in Rio de Janeiro. Public sector labs mostly engage in formulation of final dosages, and to a lesser degree on pharmochemical inputs. Flynn, “Public Production.”


36. IMS and MH data; Chamas, “Developing Innovative Capacity.”

38. Introducing pharmaceutical patents in 1997 is still early, since Brazil had until 2005.
40. Bioequivalent medicines feature the same APIs as reference drugs, and they perform identically in the human body. “Similars” may not satisfy the second criterion.
42. Interview, former President of CCyT, 10 August 2007 (Mexico City).
43. Interview, Director General of AMIIF, 14 August 2007 (Mexico City).
44. CCyT archives; interview, former official in Secretary of Government, 14 August 2007 (Mexico City).
45. As an illustration of the perversity of this legislative process, note that the original sponsors of the initiative to reform Mexico’s CL system (PVEM) ended up actively opposing the final bill that was passed in Congress.
46. “Patent Term Extensions in Mexico Buck Latin American Trend.”
50. The leading generics firms in Mexico are Israeli, British, French, and Canadian.
51. CCyT archives, letter on file with author; interview, ex-President of ANAFAM, 21 August 2007 (Mexico City).
52. Space prevents discussion of data exclusivity, but the same pattern prevails.
53. Although neither restrictions on CLs nor the type of linkage introduced in Mexico are required by NAFTA, both sorts of provisions feature in many recent RBTAs.